Business Wire

AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic

CAMBRIDGE, Mass. & TÜBINGEN, Germany--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the ...
Business Wire

AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases

CAMBRIDGE, Mass. & TÜBINGEN, Germany--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today emerged from ...
New Atlas

Beyond CRISPR: New class of gene-editing enzymes discovered

One of the most revolutionary discoveries of the century, the CRISPR gene-editing system is built on a bacterial defense mechanism that allows scientists to make precise edits to DNA. Now scientists ...
manilatimes

GenAssist Ltd Announces FDA Clearance of Investigational New Drug Application for GEN6050X, a Globally First-in-Class Base Editing Drug for Duchenne Muscular Dystrophy

GEN6050X injection is an intravenous cytosine base editing drug designed for DMD patients amenable to exon 50 skipping. GEN6050X is based on GenAssist's unique RNA editing-free Targeted AID-mediated ...
Seeking Alpha

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for ...